Highlights
1 patent
About
Neonatal Gastrointestinal Treatment
Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. The company's current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. Nutrinia's insulin formulation is a powder that can be mixed with saline or infant formula before use. It is composed of insulin with excipients already approved for infant consumption, making it a safe drug product for infants. The formulation is intended to target and treat local GI issues with no absorption or systemic exposure.
Identity
| Name | Nutrinia |
|---|---|
| Slug | nutrinia |
| Type / kind | startup |
| Crunchbase ID | nutrinia |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6YwP4IDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2020 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Bnei Brak |
| HQ address | Ha-Khilazon Street 6, Ramat Gan, Israel |
Web & social
| https://www.linkedin.com/company/11008136 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
oral-drugsgastroenterologypharmaceuticalsbabiesdoctorspatients
Funding
| Total raised | $44.1M |
|---|---|
| Current stage | Series D |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}